MAY 15, 2018 06:31 PM PDT

Rett Syndrome: Possible Drug Treatment

WRITTEN BY: Nouran Amin

A research study published in Cell Reports explains that a new drug was seen to reduce symptoms of Rett Syndrome in preclinical models while activating dormant neurons, a characteristic of this genetic disorder. The study was led by Dr. Manel Esteller, the Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL) and Dr. Sonia Guil, an investigator at the same research group.

Rett syndrome is one of the most frequent causes of intellectual disability in women second only to Down Syndrome. The main genetic cause of Rett Syndrome is mutations in the embryo that affect the MECP2 gene, which produces a protein known as a regulator for gene expression. As of now, there is no pharmacotherapies for treating this disease and current research is focused on trying to control its most serious phenotypes, such as epileptic and respiratory cries. The study was led by Dr. Manel Esteller, the Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL) and Dr. Sonia Guil, an investigator at the same research group.

Child w/ Rett Syndrome

"We knew for some years that the brains of Rett syndrome girls were inflamed, so we decided to test whether a drug that inhibits a central neuroinflammatory protein called glycogen synthase kinase-3B (GSK3B) could reverse part of the symptoms. As with any experimental treatment, we started with a preclinical model of the disease, studying it in mice that have the same MECP2 deficiency as in human Rett syndrome" explains Dr. Manel Esteller. "The results have been very promising; agent SB216763 has been able to lengthen the life of the animals, significantly reducing tremors, breathing difficulties and mobility limitations. But what is really remarkable is that the inhibition of GSK3B also causes an "awakening" of the sleeping neurons of the syndrome: these brain cells are now beginning to regain contact between them and communication between neuronal synapses increases," explains IDIBELL researcher, and he concludes: "Our findings provide a new way of improving the quality of life of these patients and now it is the neurologists' job to demonstrate their applicability in patients with Rett Syndrome. In any case, we have to be aware that the mutation in the MECP2 gene is still there, and only by correcting it would we arrive at a definitive treatment of the disease."

Source: IDIBELL-Bellvitge Biomedical Research Institute, Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 09, 2018
Drug Discovery
OCT 09, 2018
'Copper Antibiotic Peptide' Effective in Eradicating Tuberculosis
The bacterium responsible for Tuberculosis has found a way to avoid antibiotics by hiding inside the macrophages which are the specific immune cells that a...
NOV 24, 2018
Drug Discovery
NOV 24, 2018
New Anti-Malarial Drug Target in Cancer
For decades, anti-malaria drugs--known as Chloroquines, have used to treat cancer. But the role in repurposing these drugs for slowing tumor growth have ne...
DEC 17, 2018
Health & Medicine
DEC 17, 2018
Microglial Priming And Pain
Microglia are in primed states when injury happens and acute exposure to opioids activates them further creating pain sensitivity....
DEC 23, 2018
Drug Discovery
DEC 23, 2018
Buruli ulcer: promising drug for a forgotten disease
One of the most forgotten and neglected diseases is Buruli ulcer, a debilitating and stigmatized condition affecting primarily children in West and Central...
JAN 24, 2019
Drug Discovery
JAN 24, 2019
Why Do Promising Cancer Drugs Fail?
After almost 20 years of a once-promising cancer drugs known as MMP inhibitors suddenly failed in clinical trials, scientists are now eager to provide an e...
FEB 20, 2019
Drug Discovery
FEB 20, 2019
Possible New Drug To Combat African Sleeping Sickness
Scientists have teamed up to combat African sleeping sickness, which is caused by trypanosomes, unicellular protozoans transmitted by the bite of an infect...
Loading Comments...